Cassava sciences completes enrollment for pivotal phase 3 program of simufilam in alzheimer's disease

Austin, texas, nov. 06, 2023 (globe newswire) -- cassava sciences, inc. (nasdaq: sava), a biotechnology company, today announced the completion of patient enrollment in a pair of phase 3 trials to evaluate the safety and efficacy of oral simufilam versus placebo in alzheimer's disease dementia.
SAVA Ratings Summary
SAVA Quant Ranking